Why the study?
Does atrial antitachycardia pacing reduce hospital admissions and antiarrhythmic drug use in patients with recurrent supraventricular tachycardia?
Does atrial antitachycardia pacing reduce hospital admissions and antiarrhythmic drug use in patients with recurrent supraventricular tachycardia?
Answers are grounded in this paper and cite their sources.
Atrial antitachycardia pacing is an effective and safe therapy for carefully selected patients with recurrent supraventricular tachycardia, reducing hospital admissions and the need for antiarrhythmic drugs.
During a 3-year period, 22 patients with recurrent supraventricular tachycardia have been treated with antitachycardia pacemakers (Intermedics Intertach, 262-12, n = 17, and Intertach II, 262-16, n = 5). Eighty-two percent were female, the mean age was 44 +/- 14 years; 86% had atrioventricular node reentrant tachycardia. Symptoms had occurred over 11.8 +/- 7.1 years, with 3.6 hospital admissions per patient, despite 4.7 +/- 2.1 antiarrhythmic drugs. Following pacemaker implantation, during a follow-up of 14.8 +/- 11.5 months, only two patients have been readmitted to a hospital because of supraventricular tachycardia (mean 0.1 per patient). One patient is taking an antiarrhythmic agent, and four are taking beta adrenergic blocking agents. Thus, 23% are taking cardioactive drugs (it was anticipated that two patients would continue on drugs after pacemaker implantation). There have been no serious complications. Atrial antitachycardia is thus an effective therapy in carefully selected patients with recurrent supraventricular tachycardia, reducing hospital admissions for supraventricular tachycardia and reducing the need for antiarrhythmic drugs.
No takes yet. Share an insight, caveat, or question.
McComb et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: